Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 1:17 PM
Ignite Modification Date:
2025-12-26 @ 1:17 PM
NCT ID:
NCT00258206
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Diagnosis of multiple myeloma, meeting 1 of the following criteria:
* High-risk disease in first remission, as defined by the following:
* Beta-2 microglobulin \> 5.0 mg/dL
* Chromosome 13 deletion
* Primary refractory disease
* Relapsed disease after achieving a response to prior chemotherapy
* The following diagnoses are not allowed:
* POEMS syndrome
* Plasma cell leukemia
* Amyloidosis
* Nonsecretory myeloma
* No evidence of spinal cord compression
PATIENT CHARACTERISTICS:
Age
* Over 18
Performance status
* Not specified
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Not specified
Renal
* Not specified
Other
* Not pregnant or nursing
* Fertile patients must use effective contraception
* HIV negative
* Has good organ function
* Is in good physical condition
* No active infection requiring antibiotics
* No other malignancy within the past 2 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
Biologic therapy
* No persistently detectable donor cells after prior allogeneic stem cell transplantation
* No prior rituximab
Chemotherapy
* See Disease Characteristics
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* Not specified
Other
* At least 28 days since prior therapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
120 Years
Study:
NCT00258206
Study Brief:
Protocol Section:
NCT00258206